Future research may focus on three areas: (1) elucidating the interaction between CDK5RAP3 and NLRP3 inflammasome components through structural biology methods; (2) validating the regulatory role of CDK5RAP3 in disease models such as NASH and liver fibrosis; and (3) exploring screening strategies for CDK5RAP3 activators to identify candidate molecules for clinical use. Here, CDK5RAP3 is linked to Hepatic fibrosis.